

Ismail Elalamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6977421/publications.pdf>

Version: 2024-02-01

149
papers

4,125
citations

186265

28
h-index

123424

61
g-index

159
all docs

159
docs citations

159
times ranked

6921
citing authors

#	ARTICLE	IF	CITATIONS
1	Venous thrombosis risk factors in pregnant women. <i>Journal of Perinatal Medicine</i> , 2022, 50, 505-518.	1.4	8
2	Features of the novel coronavirus infection in cancer patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 15, 726-737.	0.5	1
3	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. <i>Hemato</i> , 2022, 3, 188-203.	0.6	1
4	The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. <i>Hemato</i> , 2022, 3, 204-218.	0.6	0
5	Platelets, thrombo-inflammation and cancer. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 15, 755-776.	0.5	1
6	Anticoagulants: dose control methods and inhibitors. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 16, 158-175.	0.5	2
7	Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210979.	1.7	1
8	Editor's Choice " European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 9-82.	1.5	308
9	Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era. <i>Thrombosis Research</i> , 2021, 198, 19-22.	1.7	17
10	Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up. <i>European Respiratory Journal</i> , 2021, 58, 2003677.	6.7	95
11	Clinical significance of measuring ADAMTS-13, its inhibitor and von Willebrand factor in obstetric and gynecological practice. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 93-106.	0.5	1
12	Extracellular neutrophil traps (NETs) in the pathogenesis of thrombosis and thromboinflammation. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 75-85.	0.6	8
13	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 982-991.	3.4	50
14	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007.	3.4	21
15	Heparin-induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1959-1972.	3.8	14
16	Transplantation Outcome in Recipients Engrafted With Organs Recovered From the First French Deceased Donor With a SARS-COV-2 Vaccine-induced Thrombotic Thrombocytopenia. <i>Transplantation</i> , 2021, 105, e84-e86.	1.0	3
17	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs " A Systematic Review and Meta-analysis. <i>TH Open</i> , 2021, 05, e438-e448.	1.4	7
18	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021, 05, e376-e386.	1.4	18

#	ARTICLE	IF	CITATIONS
19	Anticoagulant, anti-inflammatory, antiviral and antitumor properties of heparins. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 295-312.	0.5	3
20	The Effect of Various Types of Anticoagulant Therapy on the Reduction of Mortality in COVID-19. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 268-278.	0.6	0
21	Features of nervous system damage in antiphospholipid syndrome. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 404-414.	0.5	0
22	Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110339.	1.7	0
23	Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 499-514.	0.5	8
24	Vaccine-induced immune thrombotic thrombocytopenia: definition, risks with different vaccines, and regulatory responses. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 562-575.	0.5	1
25	Analysis of Inter-Observer Agreement of Adjudication of Colors of Pad Colors of Doac Dipstick to Determine Presence or Absence of Direct Oral Anticoagulants in Outpatients' Urine Samples. <i>Blood</i> , 2021, 138, 3213-3213.	1.4	0
26	Risk Factors in Cancer Patients. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 465-475.	0.6	2
27	Impact of LMWH and Specific Factor Xa Inhibitors, Apixaban and Fondaparinux, on Cancer Cell Biology and Procoagulant Properties of Cancer Microenvironment. <i>Blood</i> , 2021, 138, 2136-2136.	1.4	1
28	Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study. <i>Blood</i> , 2021, 138, 3207-3207.	1.4	0
29	The Compass-COVID19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. <i>Blood</i> , 2021, 138, 2121-2121.	1.4	1
30	Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells. <i>Thrombosis Research</i> , 2020, 187, 170-179.	1.7	6
31	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140.	3.4	30
32	Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2020, 95, E18-E20.	4.1	11
33	Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020, 191, S50-S57.	1.7	13
34	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1680-1690.	3.4	38
35	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628.	3.4	131
36	Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. <i>Thrombosis and Haemostasis</i> , 2020, 120, 937-948.	3.4	294

#	ARTICLE	IF	CITATIONS
37	Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1096-1107.	3.4	29
38	Hematological findings and complications of COVID-19. <i>American Journal of Hematology</i> , 2020, 95, 834-847.	4.1	1,354
39	Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962098346.	1.7	1
40	COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice. <i>Journal of Perinatal Medicine</i> , 2020, 48, 985-994.	1.4	11
41	Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome. <i>Obstetrics, Gynecology and Reproduction</i> , 2020, 14, 123-131.	0.5	24
42	Novel coronavirus infection (COVID-19) and risk groups in obstetrics and gynecology. <i>Obstetrics, Gynecology and Reproduction</i> , 2020, 14, 159-162.	0.5	5
43	Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers. <i>Obstetrics, Gynecology and Reproduction</i> , 2020, 14, 132-147.	0.5	16
44	Disseminated intravascular coagulation in perinatal medicine. <i>Obstetrics, Gynecology and Reproduction</i> , 2020, 14, 56-68.	0.5	1
45	COVID-19, hemostasis disorders and risk of thrombotic complications. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2020, 75, 306-317.	0.6	8
46	Venous thrombosis risk factors in pregnant women. <i>Journal of Perinatal Medicine</i> , 2020, .	1.4	2
47	Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process. <i>TH Open</i> , 2019, 03, e340-e347.	1.4	6
48	Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. <i>Cancers</i> , 2019, 11, 48.	3.7	16
49	Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI. <i>TH Open</i> , 2019, 03, e309-e315.	1.4	9
50	Pathogenic heparin-induced thrombocytopenia and thrombosis (HIT) antibodies determined by rapid functional flow cytometry. <i>European Journal of Haematology</i> , 2019, 103, 225-233.	2.2	6
51	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. <i>Thrombosis Journal</i> , 2019, 17, 6.	2.1	15
52	Prospective Evaluation of a Rapid Functional Assay for Heparin-Induced Thrombocytopenia Diagnosis in Critically Ill Patients*. <i>Critical Care Medicine</i> , 2019, 47, 353-359.	0.9	8
53	Early-access programme in emergency care: idarucizumab use for rapid dabigatran reversal in critical care patients. <i>European Journal of Emergency Medicine</i> , 2019, 26, 230-231.	1.1	1
54	Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study. <i>Blood</i> , 2019, 134, 2425-2425.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study. <i>Blood</i> , 2019, 134, 1913-1913.	1.4	0
56	Thrombotic microangiopathy in cancer patients. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019, 74, 323-332.	0.6	1
57	Graft Product for Autologous Peripheral Blood Stem Cell Transplantation Enhances Thrombin Generation and Expresses Procoagulant Microparticles and Tissue Factor. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 684-690.	1.7	2
58	Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 193-194.	1.7	2
59	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. <i>Oncologist</i> , 2018, 23, 1372-1381.	3.7	36
60	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. <i>Blood Cancer Journal</i> , 2018, 8, 102.	6.2	23
61	Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network. <i>Journal of Onco-Nephrology</i> , 2018, 2, 37-49.	0.6	4
62	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy Na ⁺ ve Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. The Observational ROADMAP-CAT-MM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S235-S236.	0.4	0
63	Comparison of antithrombin α -dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 696-707.	2.3	12
64	In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study. <i>Blood</i> , 2018, 132, 2014-2014.	1.4	0
65	A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS [®] Cancer-Associated Thrombosis Study. <i>Oncologist</i> , 2017, 22, 1222-1231.	3.7	167
66	The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 155-163.	1.7	5
67	Does Lipid Profile Affect Thrombin Generation During Ramadan Fasting in Patients With Cardiovascular Risks?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 980-986.	1.7	4
68	Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. <i>American Journal of Hematology</i> , 2016, 91, E455-6.	4.1	3
69	Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays. <i>Blood</i> , 2016, 128, 5020-5020.	1.4	3
70	A Clinic-Genetic Score for Risk Assessment of Recurrent Venous Thrombo Embolism. <i>Blood</i> , 2016, 128, 1428-1428.	1.4	0
71	Idarucizumab, a Specific Antidote for Dabigatran, Cross-React with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds. <i>Blood</i> , 2016, 128, 3836-3836.	1.4	0
72	Easily Performed Functional Flow Cytometry Assay for Heparin-Induced Thrombocytopenia and Thrombosis (HIT): Correlation with Clinical Presentation, Immunoassay and Serotonin-Release Assay. <i>Blood</i> , 2016, 128, 2601-2601.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Cancer cells BXP3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. <i>Thrombosis Research</i> , 2015, 136, 1273-1279.	1.7	15
74	Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 697-704.	1.7	0
75	Acquisition of Resistance to Doxorubicin By Breast Cancer Cells MCF7 Enhances Their Procoagulant Properties and Alters the Efficacy of Antithrombotic Agents to Inhibit Thrombin Generation. <i>Blood</i> , 2015, 126, 1113-1113.	1.4	0
76	Thrombosis in Cancer Patients during Hospitalization: Impact on Stays and Costs. <i>Blood</i> , 2015, 126, 4487-4487.	1.4	0
77	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. <i>Blood</i> , 2015, 126, 1074-1074.	1.4	0
78	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 423.	2.0	30
79	Unusual Case of HIT With Cardiac Arrest During Hemodialysis. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1086-1089.	1.9	1
80	Effect of Low Molecular Weight Heparins and Fondaparinux Upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXP3. <i>Current Vascular Pharmacology</i> , 2014, 12, 893-902.	1.7	9
81	The Cost of Hospitalization for Thromboembolic Events in Patients with Colon or Lung Cancer. <i>Blood</i> , 2014, 124, 3515-3515.	1.4	2
82	Use of Thrombin Generation Assay As Tool for the Evaluation of the Antithrombotic Sameness of Enoxaparin Copies. <i>Blood</i> , 2014, 124, 5092-5092.	1.4	0
83	The Impacts of Thromboembolic Events in Breast and Prostate Cancer Patients: Incidence, Hospitalization Duration and Costs. <i>Blood</i> , 2014, 124, 4828-4828.	1.4	0
84	Differential Influence of Lung Cancer Stage, Time from Diagnosis and Chemotherapy on Plasma and Cellular Biomarkers of Hypercoagulability. the Roadmap Study. <i>Blood</i> , 2014, 124, 4253-4253.	1.4	0
85	The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement. <i>Thrombosis Research</i> , 2013, 132, 685-691.	1.7	16
86	Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma. <i>Thrombosis Research</i> , 2013, 132, 584-591.	1.7	17
87	Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: Confirmation in a prospective study. <i>Platelets</i> , 2013, 24, 441-447.	2.3	33
88	MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. <i>Thrombosis and Haemostasis</i> , 2013, 110, 844-851.	3.4	52
89	Distinct Roles Of Antithrombin-Dependent Antithrombotic Agents (Lovenox, Fondaparinux) and Direct Anti-Xa Anti-Coagulant (Apixaban) On The Inhibition Of Thrombin Generation Induced By Human Pancreatic (BXP3) and Human Breast (MCF7) Cells. <i>Blood</i> , 2013, 122, 3632-3632.	1.4	2
90	A Synthetic Evaluation Of Genetic and Pharmacological Resistance To Clopidogrel and On Treatment Residual Platelet Aggregation In Patients With Atherothrombosis. <i>Blood</i> , 2013, 122, 3631-3631.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Impact Of Thrombin Generation, Tissue Factor Activity and Thrombomodulin Activity On The Positivity Of Assisted Reproductive Technique In Infertile Women. Blood, 2013, 122, 3630-3630.	1.4	0
92	Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 744-755.	5.6	56
93	Description of Response to Aspirin and Clopidogrel in Outpatients With Coronary Artery Disease Using Multiple Electrode Impedance Aggregometry. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 356-363.	1.7	6
94	C0398 Does buffy coat prepared for autologous stem cell transplantation in cancer patients has procoagulant properties? An in vitro study. Thrombosis Research, 2012, 130, S166-S167.	1.7	0
95	Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thrombosis Research, 2012, 129, 779-786.	1.7	37
96	Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thrombosis Research, 2012, 129, 101-103.	1.7	36
97	The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thrombosis and Haemostasis, 2012, 107, 1044-1052.	3.4	63
98	Hypercoagulability Linked to Breast Cancer Depends On the Stage and the Duration of the Tumor Evolution. Blood, 2012, 120, 3396-3396.	1.4	0
99	A Novel Test for the Rapid Rule Out of Heparin-Induced Thrombocytopenia Diagnosis in Intensive Care unit patients. Blood, 2012, 120, 1119-1119.	1.4	0
100	In Vitro Evaluation of the Procoagulant Properties of Autologous Peripheral Blood Stem Cell Transplant. Blood, 2012, 120, 1134-1134.	1.4	0
101	Markers of Hypercoagulability in Breast Cancer: What Is Their Clinical Relevance?. Blood, 2012, 120, 5133-5133.	1.4	0
102	Heparin-induced skin necrosis: HIT-2 without thrombocytopenia. Intensive Care Medicine, 2011, 37, 172-173.	8.2	13
103	The Effects of Hydroxyurea on the Thrombin Generation and Microparticles in Sickle Cell Anemia Patients. Blood, 2011, 118, 2292-2292.	1.4	0
104	Effect of two oral doses of 17 β -estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double-blind placebo-controlled study. Fundamental and Clinical Pharmacology, 2010, 24, 239-245.	1.9	1
105	2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group. Critical Reviews in Oncology/Hematology, 2010, 73, 31-46.	4.4	78
106	Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. International Journal of Hematology, 2010, 92, 296-301.	1.6	41
107	Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. Journal of Thrombosis and Thrombolysis, 2010, 29, 108-113.	2.1	7
108	Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease. Blood Coagulation and Fibrinolysis, 2010, 21, 674-678.	1.0	9

#	ARTICLE	IF	CITATIONS
109	The GPIIb/IIIa polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. <i>Thrombosis Research</i> , 2010, 125, e265-e268.	1.7	19
110	Prevalence of Risk Factors for VTE In Hospitalized Medical and Surgical Patients. Data From the Comparison of Methods for Thromboembolic Risk Assessment with Clinical Perceptions and Awareness In Real Life Surgical and Medical Patients (COMPASS) Study. <i>Blood</i> , 2010, 116, 3337-3337.	1.4	1
111	Comparison of Seven Generic Enoxaparin with Lovenox® on In Vitro Cross-Reactivity with Antibodies From Heparin Induced Thrombocytopenia.. <i>Blood</i> , 2010, 116, 1105-1105.	1.4	5
112	Platelet Microparticle Generation Assay: a Valuable and Simpler Alternative to 14C-SRA for Type-II HIT Diagnosis.. <i>Blood</i> , 2010, 116, 1442-1442.	1.4	0
113	Structural Determinants of Enoxaparin Oligosaccharides for the Down-Regulation of Tissue Factor Induced Factor VIIa Generation In Human Plasma.. <i>Blood</i> , 2010, 116, 1106-1106.	1.4	0
114	Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs. <i>Blood</i> , 2010, 116, 3334-3334.	1.4	0
115	Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. <i>Thrombosis and Haemostasis</i> , 2009, 102, 42-48.	3.4	16
116	Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 428-434.	1.7	15
117	Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease. <i>Thrombosis Research</i> , 2009, 123, 640-643.	1.7	10
118	Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2009, 124, 554-559.	1.7	28
119	Cryofibrinogenemia: New Insights into Clinical and Pathogenic Features. <i>American Journal of Medicine</i> , 2009, 122, 1128-1135.	1.5	73
120	Steady State Sickle Cell Anemia Is Associated with Increased Formation of Erythrocyte-Derived Microparticles and Acceleration of Thrombin Generation.. <i>Blood</i> , 2009, 114, 4001-4001.	1.4	2
121	Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?. <i>Supportive Care in Cancer</i> , 2008, 16, 1333-1341.	2.2	23
122	In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. <i>Thrombosis Research</i> , 2008, 121, 493-497.	1.7	20
123	JAK2V617F mutation is not associated with unexplained recurrent arterial and venous thrombosis. <i>Thrombosis Research</i> , 2008, 122, 427-428.	1.7	11
124	Endothelial cell markers' kinetics following umbilical cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2008, 49, 2209-2212.	1.3	3
125	Screening for aspirin resistance in stable coronary artery patients by three different tests. <i>Thrombosis Research</i> , 2007, 121, 413-418.	1.7	37
126	Differential Procoagulant Phenotype of Pancreatic and Breast Cancer Cells Related to Different Tissue Factor Activity.. <i>Blood</i> , 2007, 110, 3992-3992.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Platelets and Heparin Induced Thrombocytopenia Antibodies Do Not Influence the Inhibitory Activity of Argatroban on Thrombin Generation.. Blood, 2007, 110, 929-929.	1.4	0
128	Endothelial Cell Markers Kinetics Following Umbilical Cord Blood Transplantation in Adults.. Blood, 2007, 110, 4964-4964.	1.4	0
129	Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood. Thrombosis and Haemostasis, 2007, 97, 109-18.	3.4	5
130	The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile. Thrombosis and Haemostasis, 2006, 95, 822-8.	3.4	12
131	Inhibition of In Vitro Thrombin Generation: Another Parameter Reinforcing the LMWH Heterogeneity.. Blood, 2005, 106, 912-912.	1.4	1
132	Circulating Platelet-Leukocyte Aggregates as a Marker of Microvascular Lesions in Diabetic Patients.. Blood, 2005, 106, 3965-3965.	1.4	0
133	In Vitro Effect of Danaparoid Sodium (Orgaran®) on Thrombin Generation after Minimal Tissue Factor Pathway Activation.. Blood, 2005, 106, 4151-4151.	1.4	0
134	Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thrombosis and Haemostasis, 2004, 91, 531-537.	3.4	50
135	In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thrombosis and Haemostasis, 2004, 92, 1296-1302.	3.4	32
136	<i>in vitro</i> aspirin resistance detected by PFA ¹⁰⁰ ™ closure time: pivotal role of plasma von Willebrand factor. British Journal of Haematology, 2004, 124, 80-85.	2.5	102
137	The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thrombosis and Haemostasis, 2004, 91, 977-985.	3.4	50
138	Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagulation and Fibrinolysis, 2004, 15, 149-156.	1.0	41
139	Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. British Journal of Haematology, 2003, 123, 327-334.	2.5	28
140	In vitro effect of melagatran and lepirudin on clot-bound thrombin. Thrombosis Research, 2003, 110, 249-252.	1.7	7
141	On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma. Blood Coagulation and Fibrinolysis, 2003, 14, 633-638.	1.0	7
142	TNF- α , inefficient by itself, potentiates IL-1 β -induced PGHS-2 expression in human pulmonary microvascular endothelial cells: requirement of NF- κ B and p38 MAPK pathways. British Journal of Pharmacology, 2002, 136, 1005-1014.	5.4	24
143	Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty. , 1998, 45, 329-331.		5
144	Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets. Thrombosis Research, 1997, 86, 255-262.	1.7	2

#	ARTICLE	IF	CITATIONS
145	Signal transduction involved in the platelet adenylate cyclase sensitization associated with PGH 2 /TxA 2 receptor desensitization. <i>British Journal of Haematology</i> , 1997, 99, 190-196.	2.5	3
146	Evidence for cAMP-dependent Platelet Ectoprotein Kinase Activity That Phosphorylates Platelet Glycoprotein IV (CD36). <i>Journal of Biological Chemistry</i> , 1996, 271, 24776-24780.	3.4	48
147	Prevalence and Patient Profile in Activated Protein C Resistance. <i>American Journal of Clinical Pathology</i> , 1995, 104, 450-454.	0.7	13
148	COVID-19, septic shock and syndrome of disseminated intravascular coagulation syndrome. Part 1. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 0, , .	0.6	11
149	COVID-19, septic shock and syndrome of disseminated intravascular coagulation syndrome. Part 2. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 0, , .	0.6	6